Primary liver carcinoma may be misclassified based solely on major imaging features

August 01, 2016

A study released in the July 2016 issue of the American Journal of Roentgenology found that biphenotypic primary liver carcinoma (also called hepatocholangiocarcinoma) may be misclassified as hepatocellular carcinoma (HCC) if interpretation is based on major imaging features alone.

"Most of these malignancies have at least one ancillary feature that may allow them to be correctly classified as a non-HCC malignancy. The results of our study support the importance of a more comprehensive algorithm for liver lesion assessment, such as Liver Imaging Reporting and Data Systems (LI-RADS)," said study lead author Theodora A. Potretzke, formerly of the Mallinckrodt Institute of Radiology, Washington University, St. Louis and now at Mayo Clinic Rochester.

Titled, "Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases," the study is based on a retrospective review of a prospectively maintained database of all pathologically proven cases of biphenotypic primary liver carcinoma treated at the Mallinckrodt Institute of Radiology between 2006 and 2014.

In the study, LI-RADS was accurate for classifying most of the biphenotypic primary liver carcinomas as non-HCC malignancy, in large part because of the inclusion of ancillary features, such as peripheral arterial phase hyperenhancement. Through evaluation of major features alone, 33 of 61 (54.1%) lesions met the criteria for HCC and therefore might have been misclassified, the study said.

"Our study provided valuable information regarding the frequency of major and ancillary features of biphenotypic primary liver carcinoma. That a substantial percentage of lesions met strictly applied major feature criteria for HCC raises concern that the use of imaging algorithms that do not account for ancillary features may lead to misdiagnosis in some instances," Potretzke said.
-end-
The study's abstract may be viewed here, while the July 2016 issue AJR of AJR may be accessed here.

Founded in 1900, ARRS is the first and oldest radiology society in the United States, and is an international forum for progress in radiology. The Society's mission is to improve health through a community committed to advancing knowledge and skills in radiology. ARRS achieves its mission through an annual scientific and educational meeting, publication of the American Journal of Roentgenology (AJR) and InPractice magazine, topical symposia and webinars, and print and online educational materials. ARRS is located in Leesburg, VA.

American Roentgen Ray Society

Related Hepatocellular Carcinoma Articles from Brightsurf:

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
Volume 11, Issue 28 of Oncotarget features ''Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation'' by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs.

Oncotarget: GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma
The cover for issue 36 of Oncotarget features Figure 7, 'Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model,' by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood.

A 3D biofabricated cutaneous squamous cell carcinoma tissue model
The cover for issue 27 of Oncotarget features Figure 4, ''(A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period,'' by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

Contrast-enhanced ultrasound predicts nodule transformation to hepatocellular carcinoma
An article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology has identified sonographic biomarkers that can predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma (HCC).

Lifetime indoor tanning associated with squamous cell carcinoma cancer
This observational study used data from nearly 160,000 women in Norway to examine lifetime indoor tanning and risk of squamous cell carcinoma, one of the most common types of cancer worldwide.

Aspirin improves liver function after embolization of hepatocellular carcinoma
Aspirin therapy is associated with both improved liver function test results and survival after transarterial embolization for hepatocellular carcinoma, according to an ahead-of-print article by F.

Percutaneous ablation vs. surgery for hepatocellular carcinoma
Compared to surgery, percutaneous liver ablation interventions (IRs) in patients with hepatocellular carcinoma (HCC) are associated with lower inhospital mortality, length of hospital stay (LOS), and hospitalization costs, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii.

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma
A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells.

New combined treatment shows promise in hepatocellular carcinoma
New combined treatment shows promise in Hepatocellular Carcinoma. A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival.

Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis.

Read More: Hepatocellular Carcinoma News and Hepatocellular Carcinoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.